Advisory Board
Introducing ACI’s Biosimilars & Innovator Biologics Advisory Board
American Conference Institute’s Biosimilars & Innovator Biologics Advisory Board was created as a part of ACI’s ongoing effort to provide industry leading content and a world-renowned speaker faculty. The board is composed of a selection of all-in-house advisers, including senior IP/Patent counsel from the leading pharmaceutical companies in the country and in some cases the world. This ‘inner circle’ counsels ACI on the impact of litigation trends and emerging topics.
Ali I. Ahmed
Global Head, Industry Advisory & Innovation, Pharmaceuticals and Therapeutics Salesforce
Rebecca Charnas Grant
Senior Director | Associate General Counsel Genentech
Larry Coury
Vice-President, Associate General Counsel Regeneron Pharmaceuticals
Henry Gu
SVP, Head of IP Zentalis Pharmaceuticals
Brian McCormick
Vice President - Chief Regulatory Counsel, Head of Global Regulatory Policy Teva Pharmaceuticals
Mira A. Mulvaney
Associate VP – Assistant General Patent Counsel, IP Litigation Eli Lilly and Company
Sonia Tadjalli Oskouei
Vice President, Biosimilars and Specialty Sandoz, Inc.
Dracey Poore
Director of Biosimilars Product and Solutions Marketing Cardinal Health
Chuck Sholtz
Vice President, Intellectual PropertyLegal Department Nutcracker Therapeutics, Inc.
Paul Walden, Ph.D
Vice-President, Medical Affairs Celltrion Healthcare Co., Ltd.